Our study demonstrates that dinaciclib, a serine/threonine kinase inhibitor against CDK1, 2, 5, and 9, inhibited tumor growth in TNBC PDXs and cell line models in vitro and in vivo, by arresting cells in the G2-M phase and inducing apoptosis. The gene discussed is MARK2; the disease is neoplasm.